55-minute voice-recorded PowerPoint presentation, providing an overview of large-cell or high-grade lymphoma in dogs, including the biologic behaviour, prognosis and treatment options.

The main focus of this presentation will be on two new anticancer drugs that can play a role in the management of canine lymphoma, Laverdia (verdinexor), which is administered orally twice a week, and Tanovea (rabacfosadine), which is administered intravenously every three weeks. For each of these two drugs, veterinarians will learn the clinical indications, how to give the drug, and how to monitor for side effects.

This lecture will also introduce a novel oral clinical trial drug available for dogs with B-cell lymphoma in Australia (13th August 2022).

Upon completion, an online quiz can be taken (unlimited attempts). Feedback will be provided after the quiz. A CPD certificate equivalent to 1 structured CPD point (as per the AVA VetEd Points) is available for this presentation. Please email The Pet Oncologist after passing the quiz.

Copyright © The Pet Oncologist 2022. All Rights Reserved. Unauthorised distribution is prohibited.